Download PDF
Der Nuklearmediziner 2006; 29(3): 207-212
DOI: 10.1055/s-2006-942137
Funktionell-morphologische Kombinationsbildgebung

© Georg Thieme Verlag Stuttgart · New York

Schlüssel-Technologie PET/CT - Nutzen, Kosten, Erwartungen

Key Technology PET/CT: Usefulness, Costs, ExpectationsG. Hör1 , W. Mohnike1
  • 1Diagnostisch-Therapeutisches Zentrum (DTZ) Berlin
Further Information

Publication History

Publication Date:
15 September 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die PET/CT kann als die derzeit umfassendste Untersuchungsmethode in der Onkologie angesehen werden. Sie vereint eine praxistaugliche Untersuchungstechnik für den Ganzkörper, betont die Stärken nuklearmedizinischer Diagnostik und verknüpft diese mit radiologischen Domänen. In Zeiten knapper Ressourcen wird es darauf ankommen, diagnostische Leitpfade, Qualitätszertifizierungen und Mengenbegrenzungsstrategien zu entwickeln, die eine möglichst frühzeitige und therapierelevante Nutzung der PET(/CT) gestatten.

Abstract

PET/CT has been established as the most comprehensive imaging modality in oncology. This innovative method combines simplified examinations techniques for whole body imaging, emphasizes the strength of nuclear medicine and combines these with radiological procedures. Further development of these combined imaging modalities requires to develop integrated diagnostic pathways, instruments of quality control and strategies to limit the number of examinations in order to assure the earliest and therapy relevant use of PET(/CT).

Schlüsselwörter

PET/CT - Kosten - FDG

Key words

PET/CT - cost - FDG

Literatur

  • 1 Bundesministerium für Gesundheit .Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses nach § 91 Abs. 7 des Fünften Buches Sozialgesetzbuch (SGB V) zur Positronenemissionstomographie. BAnz. 2.3.2006; 43: 1374
    Google Scholar
  • 2 DTZ Berlin .„PET/CT als therapiesteuerndes Instrument in der onkologischen Diagnostik”. In: Mohnike W (Hrsg). 4. Berliner PET/CT-Symposium 2006
    Google Scholar
  • 3 PET e. V .„PET/CT zwischen Innovationsförderung und Mengenproblem”. Protokoll zum Petersberger Gespräch zum Aspekt der Innovationsimplementierung. www.bdn-online.de 2006
    Google Scholar
  • 4 Bengel F M. Is the future of nuclear medicine written in the genes?.  Eur J Nucl Med Mol Imaging. 2004;  31 309-311
    CrossrefPubMedGoogle Scholar
  • 5 Bengel F M. Noninvasive imaging of cardiac gene expression and its future implications for molecular therapy (Review Article).  Mol Imaging Biol. 2005;  7 22-29
    CrossrefPubMedGoogle Scholar
  • 6 Bengel F M, Anton M, Richter T. et al . Noninvasive imaging of transgene expression by use of positron emission tomography in a pig model of myocardial gene transfer.  Circulation. 2003;  108 2127-2133
    CrossrefPubMedGoogle Scholar
  • 7 Cohade C, Osman M, Leal J, Wahl R L. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma.  J Nucl Med. 2003;  44 1797-1803
    PubMedGoogle Scholar
  • 8 Dietlein M, Schicha H. Vergütung der PET bei onkologischen Fragestellungen in Europa: eine Umfrage.  Nuklearmedizin. 2003;  42 80-85
    PubMedGoogle Scholar
  • 9 Freudenberg L S, Antoch G, Schütt P. et al . FDG-PET/CT in restaging of patients with lymphoma.  Eur J Nucl Med Molec Imaging. 2004;  31 325-329
    CrossrefPubMedGoogle Scholar
  • 10 Herholz K, Nordberg A, Salmon E. et al . Metabolic impairment of associations cortex predicts progression in Alzheimer's disease: a prospective multicenter positron emission tomography study (PET).  Eur J Neurol. 1998;  5 S24
    PubMedGoogle Scholar
  • 11 Herholz K, Schopphoff H, Schmidt M. et al . Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.  J Nucl Med. 2002;  43 21-26
    PubMedGoogle Scholar
  • 12 Hoskin P J. PET in lymphoma:what are the oncologists needs?.  Eur J Nucl Med. 2003;  30 (Suppl 1) S37-S41
    PubMedGoogle Scholar
  • 13 Juweid M E, Wiseman G, Mendal Y. et al . Integrated positron emission tomography/computed tomography-based response classification for non-Hodgkin's lymphoma (Abstr. No. 66).  Molecular Imaging and Biology. 2004;  6 86
    PubMedGoogle Scholar
  • 14 Kaufmann P A. Die zukünftige Rolle von PET in der Kardiologie.  Der Nuklearmediziner. 2004;  27 208-212
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Körholz D, Kluge R, Wickmann L. et al . Importance of F-18 fluorodeoxy D-2 glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GHPOH-HD 2003 protocol.  Onkologie. 2003;  26 489-493
    CrossrefPubMedGoogle Scholar
  • 16 Krause B J, Blumstein N M, Schäfer S. et al . Evaluation of F-18-FDG PET/CT in patients suspected of local recurrence of colorectal cancer introduced to external conformal radiotherapy.  Eur J Nucl Med Mol Imaging. 2004;  31 S285
    PubMedGoogle Scholar
  • 17 Mohnike W, Hör G. PET/CT-Atlas. Springer, Berlin, Heidelberg 2006
    Google Scholar
  • 18 Namdar M, Hany T F, Burger C. et al . Combined computed tomography-angiogram and positron emission tomography perfusion imaging for assessment of coronary artery disease in a novel PET/CT: A pilot feasibility study.  J Am Coll Cardiol. 2003;  41 (Suppl A) 439A
    PubMedGoogle Scholar
  • 19 Namdar M, Hany T F, Koepfli P. et al . Integrated PET/CT for the assessment of coronary artery disease: A feasibility study.  J Nucl Med. 2005;  46 930-935
    PubMedGoogle Scholar
  • 20 Oberender P. Kosten-Nutzen-Analyse der PET- und PET/CT-Diagnostik am Beispiel des nicht-kleinzelligen Bronchialkarzinoms (NSCLC). Diagn. Therapeut. Zentrum/BDN 2004
    Google Scholar
  • 21 Osman M M, Cohade C H, Fishman E F, Wahl R. Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: Frequency in 250 patients.  J Nucl Med. 2005;  46 1352-1355
    PubMedGoogle Scholar
  • 22 Schlag P, Lehner B, Strauss L G, Georgi P, Herfarth C H. Scar or recurrent rectal cancer (Positron emission tomography is more helpful for diagnosis than immunoscintigraphy).  Arch Surg. 1989;  124 197-200
    PubMedGoogle Scholar
  • 23 Schroeder F. The European randomized study of screening prostate cancer (ERSCP).  Br J Radiol. 1997;  79 68-71
    PubMedGoogle Scholar
  • 24 Townsend D W. PET/CT today and tomorrow.  JNM. 2004;  45 4S-14S
    PubMedGoogle Scholar
  • 25 van Tinteren H, Hoekstra O S, Smit E F. et al . Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non small cell lung cancer: The PLUS multicentre randomized trial.  Lancet. 2002;  359 1388-1392
    CrossrefPubMedGoogle Scholar
  • 26 Schulthess G K von. Maximizing the benefit of integrated PET/CT: the road ahead.  Eur J Nucl Med Mol Imaging. 2004;  31 1462-1463
    CrossrefPubMedGoogle Scholar
  • 27 Wahl R. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT.  JNM. 2004;  45 82S-95S
    PubMedGoogle Scholar

Prof. Dr. med. em. G. Hör

Diagnostisch-Therapeutisches Zentrum (DTZ) Berlin

Kadiner Str. 23

10243 Berlin

Phone: +49/30/5 59 68 61

Email: nuklearmedizin@berlin-diagnostik.de

      >